FulvestrantA Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

被引：0
|
作者：
Jamie D. Croxtall
Kate McKeage
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Tamoxifen; Postmenopausal Woman; Anastrozole; Exemestane; Fulvestrant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fulvestrant (Faslodex®) is an intramuscularly administered steroidal estrogen receptor antagonist that is devoid of any known estrogen agonist effects. It is indicated as second-line therapy for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who have progressed following prior endocrine therapy.
引用
收藏
页码：363 / 380
页数：17
相关论文
共 50 条
12345